Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMRN News
Morgan Stanley Bullish on Dividend Stocks
1d ago
CNBC
BioMarin's Voxzogo Phase 3 Data Shows Positive Results
May 20 2026
seekingalpha
BioMarin's VOXZOGO Study Achieves Significant Growth Milestones
May 20 2026
PRnewswire
BioMarin's VOXZOGO Study Achieves Significant Growth Milestones
May 20 2026
Newsfilter
BioMarin's BMN 401 Phase 3 Trial Results Mixed
May 18 2026
seekingalpha
BioMarin's ENERGY 3 Study Results on ENPP1 Deficiency
May 18 2026
PRnewswire
BioMarin's ENPP1 Deficiency Study Results Show Mixed Outcomes
May 18 2026
Newsfilter
Emerging Trends in Rare Disease Drug Development
May 07 2026
CNBC
BioMarin Q1 Earnings: Amicus Acquisition Fuels Growth
May 05 2026
seekingalpha
BioMarin Reports Significant Revenue Growth in Q1 2026
May 04 2026
PRnewswire
VOXZOGO Shows Positive Long-Term Effects on Children's Bone Health
May 02 2026
PRnewswire
New Research on VOXZOGO in Children with Achondroplasia
May 02 2026
Newsfilter
BioMarin Pharmaceutical Q1 Earnings Announcement Scheduled
May 01 2026
seekingalpha
BioMarin Acquires Amicus for $4.8 Billion to Enhance Rare Disease Portfolio
Apr 27 2026
PRnewswire
Intellia's Gene Editing Therapy Trial Achieves Success
Apr 27 2026
CNBC
BioMarin to Host Q1 2026 Financial Results Call on May 4
Apr 27 2026
PRnewswire
Show More News
